Alfa Oncology is your trusted, experienced team. We are dedicated to providing optimization services for monoclonal antibodies (mAbs) against pancreatic cancer (PC). Our extensive knowledge of monoclonal antibody-based drug development and complex PC biology allows us to help our clients achieve optimal study design and rapid research start-ups. Based on our advanced modification platform, we are able to humanize antibodies to improve their potency and facilitate the development of antibody drugs against PC.
Challenges in antibody-drug research and development.
- Lower expression levels
- Antibody aggregation and instability
- Lack of the desired affinity
The service offering at Alfa Oncology
- Antibody engineering
Our platform is capable of simultaneously optimizing different key antibody properties, including expression, thermostability, aggregation, affinity, and so on. By combining structural modeling with internal databases, we can efficiently perform structural simulations of antibodies. Computer simulations based on antigen-antibody complexes or antibody structures guide antibody optimization. Potential amino acid changes within the complementary determining regions (CDRs) are ranked based on evolutionary conservatism and physicochemical properties. Multiple variant antibodies are then designed to incorporate the highest-ranked substitutions. Finally, the antibody variants are expressed and their properties are measured. Machine learning is used to analyze these data.
- Antibody affinity maturation
Among key properties, affinity is a key parameter of antibody drugs, which usually affects the function and efficacy of antibodies. In addition to guiding the optimization of the affinity of antibodies and antigens by means of computer simulations, we also offer traditional phage display-based affinity maturation methods that can guarantee affinity enhancement to the nM level.
- Antibody humanization
Human anti-mouse antibody reaction (HAMA) seriously affects the safety and efficacy of murine-derived antibody therapy. Antibody humanization and characterization is an essential step in the process of therapeutic antibody discovery, which reduces the immunogenicity of mAbs from xenogeneic sources and increases their activation of the human immune system by replacing the non-human antibody framework with a human antibody framework. Our antibody humanization service combines CDR transplantation and back mutation, allowing for humanization while retaining original affinity and function.
- Developability assessment
Early developability assessment is important as a link between drug discovery and drug development. We provide professional biopharmaceutical development feasibility assessment services to assess the potential risk of manufacturing or clinical failure for candidate antibody protein molecules at the early stages of antibody and protein drug discovery. Our services include post-translational modification, molecular stability, and physicochemical property assessment services. We can help our clients rapidly narrow down the candidate molecules at the early stage of drug development, screen for the most active and suitable candidates for drug discovery, reduce the risk of late-stage development, and contribute to the success of the project.
Benefits of our services
- Years of experience in antibody engineering and optimization
- Extensive knowledge of monoclonal antibody-based drug development and complex PC biology
- Well-established monoclonal antibody drug optimization platform
- Tailored solutions to customers' satisfaction
- Fast turnaround time without compromising quality
Our customer service representatives are available 24 hours a day from Monday to Sunday. If you are interested in our services, please contact us for more details.